Am J Psychiatry 158:176-184, February 2001
© 2001 American Psychiatric Association
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Philip D. Harvey, Ph.D., and
Richard S.E. Keefe, Ph.D.
OBJECTIVE: Novel antipsychotic medications have been reported to have beneficial effects on cognitive functioning in patients with schizophrenia. However, these effects have been assessed in studies with considerable variation in methodology. A large number of investigator-initiated and industry-sponsored clinical trials are currently underway to determine the effect of various novel antipsychotics on cognitive deficits in patients with schizophrenia. The ability to discriminate between high- and low-quality studies will be required to understand the true implications of these studies and their relevance to clinical practice. METHOD: This article addresses several aspects of research on cognitive enhancement in schizophrenia, emphasizing how the assessment of cognitive function in clinical trials requires certain standards of study design to lead to interpretable results. RESULTS: Novel antipsychotic medications appear to have preliminary promise for the enhancement of cognitive functioning. However, the methodology for assessing the treatment of cognitive deficits is still being developed. CONCLUSIONS: Researchers and clinicians alike need to approach publications in this area with a watchful eye toward methodological weaknesses that limit the interpretability of findings.
This article has been cited by other articles:
|
|
|
|
 
R. S. E. Keefe and P. D. Harvey
Implementation Considerations for Multisite Clinical Trials with Cognitive Neuroscience Tasks
Schizophr Bull,
July 1, 2008;
34(4):
656 - 663.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman, R. E. Drake, L. I. Sederer, A. Belger, R. Keefe, D. Perkins, and S. Stroup
Science and Recovery in Schizophrenia
Psychiatr Serv,
May 1, 2008;
59(5):
487 - 496.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Swartz
Introduction to the CATIE Special Section
Psychiatr Serv,
May 1, 2008;
59(5):
497 - 499.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Parks, A. Radke, G. Parker, M.-E. Foti, R. Eilers, M. Diamond, D. Svendsen, and R. Tandon
Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment
Schizophr Bull,
April 2, 2008;
(2008)
sbn019v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Szoke, A. Trandafir, M.-E. Dupont, A. Meary, F. Schurhoff, and M. Leboyer
Longitudinal studies of cognition in schizophrenia: meta-analysis
The British Journal of Psychiatry,
April 1, 2008;
192(4):
248 - 257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lewis and J. Lieberman
CATIE and CUtLASS: can we handle the truth?
The British Journal of Psychiatry,
March 1, 2008;
192(3):
161 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Silverstein, W. D. Spaulding, A. A. Menditto, A. Savitz, R. P. Liberman, S. Berten, and H. Starobin
Attention Shaping: a Reward-Based Learning Method to Enhance Skills Training Outcomes in Schizophrenia
Schizophr Bull,
January 22, 2008;
(2008)
sbm150v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Stone and L. J. Seidman
Toward a Model of Memory Enhancement in Schizophrenia: Glucose Administration and Hippocampal Function
Schizophr Bull,
January 1, 2008;
34(1):
93 - 108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Schwalbe and A. Medalia
Cognitive Dysfunction and Competency Restoration: Using Cognitive Remediation to Help Restore the Unrestorable
J Am Acad Psychiatry Law,
December 1, 2007;
35(4):
518 - 525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. F. O'Donnell
Cognitive Impairment in Schizophrenia: A Life Span Perspective
American Journal of Alzheimer's Disease and Other Dementias,
November 1, 2007;
22(5):
398 - 405.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Morein-Zamir, D. C. Turner, and B. J. Sahakian
A Review of the Effects of Modafinil on Cognition in Schizophrenia
Schizophr Bull,
November 1, 2007;
33(6):
1298 - 1306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Sergi, M. F. Green, C. Widmark, C. Reist, S. Erhart, D. L. Braff, K. S. Kee, S. R. Marder, and J. Mintz
Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol
Am J Psychiatry,
October 1, 2007;
164(10):
1585 - 1592.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Gray and B. L. Roth
Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia
Schizophr Bull,
September 1, 2007;
33(5):
1100 - 1119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S.E. Keefe, J. A. Sweeney, H. Gu, R. M. Hamer, D. O. Perkins, J. P. McEvoy, and J. A. Lieberman
Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison
Am J Psychiatry,
July 1, 2007;
164(7):
1061 - 1071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Morrens, W. Hulstijn, and B. Sabbe
Psychomotor Slowing in Schizophrenia
Schizophr Bull,
July 1, 2007;
33(4):
1038 - 1053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Heinrichs
Cognitive Improvement in Response to Antipsychotic Drugs: Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Arch Gen Psychiatry,
June 1, 2007;
64(6):
631 - 632.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. E. Keefe, R. M. Bilder, S. M. Davis, P. D. Harvey, B. W. Palmer, J. M. Gold, H. Y. Meltzer, M. F. Green, G. Capuano, T. S. Stroup, et al.
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Arch Gen Psychiatry,
June 1, 2007;
64(6):
633 - 647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Harvey, C. R. Bowie, and A. Loebel
Neuropsychological Normalization With Long-Term Atypical Antipsychotic Treatment: Results of a Six-Month Randomized, Double-Blind Comparison of Ziprasidone vs. Olanzapine.
J Neuropsychiatry Clin Neurosci,
December 1, 2006;
18(1):
54 - 63.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Harvey, T. L. Patterson, L. S. Potter, K. Zhong, and M. Brecher
Improvement in Social Competence With Short-Term Atypical Antipsychotic Treatment: A Randomized, Double-Blind Comparison of Quetiapine Versus Risperidone for Social Competence, Social Cognition, and Neuropsychological Functioning
Am J Psychiatry,
November 1, 2006;
163(11):
1918 - 1925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Roder, D. R. Mueller, K. T. Mueser, and H. D. Brenner
Integrated Psychological Therapy (IPT) for Schizophrenia: Is It Effective?
Schizophr Bull,
October 1, 2006;
32(suppl_1):
S81 - S93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Seidman, A. J. Giuliano, C. W. Smith, W. S. Stone, S. J. Glatt, E. Meyer, S. V. Faraone, M. T. Tsuang, and B. Cornblatt
Neuropsychological Functioning in Adolescents and Young Adults at Genetic Risk for Schizophrenia and Affective Psychoses: Results from the Harvard and Hillside Adolescent High Risk Studies
Schizophr Bull,
July 1, 2006;
32(3):
507 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Thornton, J. X. Van Snellenberg, A. A. Sepehry, and W. G. Honer
The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review
J Psychopharmacol,
May 1, 2006;
20(3):
335 - 346.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. E. Snitz, A. MacDonald III, J. D. Cohen, R. Y. Cho, T. Becker, and C. S. Carter
Lateral and Medial Hypofrontality in First-Episode Schizophrenia: Functional Activity in a Medication-Naive State and Effects of Short-Term Atypical Antipsychotic Treatment
Am J Psychiatry,
December 1, 2005;
162(12):
2322 - 2329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Harvey, J. Rabinowitz, M. Eerdekens, and M. Davidson
Treatment of Cognitive Impairment in Early Psychosis: A Comparison of Risperidone and Haloperidol in a Large Long-Term Trial
Am J Psychiatry,
October 1, 2005;
162(10):
1888 - 1895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Medalia and R. Richardson
What Predicts a Good Response to Cognitive Remediation Interventions?
Schizophr Bull,
October 1, 2005;
31(4):
942 - 953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Breier
Developing Drugs for Cognitive Impairment in Schizophrenia
Schizophr Bull,
October 1, 2005;
31(4):
816 - 822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J Hagan and D. N C Jones
Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia
Schizophr Bull,
October 1, 2005;
31(4):
830 - 853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Gardner, R. J. Baldessarini, and P. Waraich
Modern antipsychotic drugs: a critical overview
Can. Med. Assoc. J.,
June 21, 2005;
172(13):
1703 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Talamini, M. Meeter, B. Elvevag, J. M. J. Murre, and T. E. Goldberg
Reduced Parahippocampal Connectivity Produces Schizophrenia-like Memory Deficits in Simulated Neural Circuits With Reduced Parahippocampal Connectivity
Arch Gen Psychiatry,
May 1, 2005;
62(5):
485 - 493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Nasrallah, S. D. Targum, R. Tandon, J. S. McCombs, and R. Ross
Defining and Measuring Clinical Effectiveness in the Treatment of Schizophrenia
Psychiatr Serv,
March 1, 2005;
56(3):
273 - 282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Harvey, B. W. Palmer, R. K. Heaton, S. Mohamed, J. Kennedy, and A. Brickman
Stability of Cognitive Performance in Older Patients With Schizophrenia: An 8-Week Test-Retest Study
Am J Psychiatry,
January 1, 2005;
162(1):
110 - 117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W Buchanan, M. Davis, D. Goff, M. F Green, R. S E Keefe, A. C Leon, K. H Nuechterlein, T. Laughren, R. Levin, E. Stover, et al.
A Summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia
Schizophr Bull,
January 1, 2005;
31(1):
5 - 19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Y. Meltzer, L. Arvanitis, D. Bauer, W. Rein, and Meta-Trial Study Group
Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder
Am J Psychiatry,
June 1, 2004;
161(6):
975 - 984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S.E. Keefe, L. J. Seidman, B. K. Christensen, R. M. Hamer, T. Sharma, M. M. Sitskoorn, R. R.J. Lewine, D. A. Yurgelun-Todd, R. C. Gur, M. Tohen, et al.
Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol
Am J Psychiatry,
June 1, 2004;
161(6):
985 - 995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Bellack, N. R. Schooler, S. R. Marder, J. M. Kane, C. H. Brown, and Y. Yang
Do Clozapine and Risperidone Affect Social Competence and Problem Solving?
Am J Psychiatry,
February 1, 2004;
161(2):
364 - 367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. W. Palmer, M. W. Bondi, E. W. Twamley, L. Thal, S. Golshan, and D. V. Jeste
Are Late-Onset Schizophrenia Spectrum Disorders Neurodegenerative Conditions? Annual Rates of Change on Two Dementia Measures
J Neuropsychiatry Clin Neurosci,
February 1, 2003;
15(1):
45 - 52.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. P. GOOD, I. KISS, C. BUITEMAN, H. WOODLEY, Q. RUI, D. WHITEHORN, and L. KOPALA
Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis
The British Journal of Psychiatry,
September 1, 2002;
181
(43):
s45 - s49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Friedman, P. D. Harvey, S. R. McGurk, L. White, M. Parrella, T. Raykov, T. Coleman, D. N. Adler, and K. L. Davis
Correlates of Change in Functional Status of Institutionalized Geriatric Schizophrenic Patients: Focus on Medical Comorbidity
Am J Psychiatry,
August 1, 2002;
159(8):
1388 - 1394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Bilder, R. S. Goldman, J. Volavka, P. Czobor, M. Hoptman, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. McEvoy, M. Kunz, et al.
Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective Disorder
Am J Psychiatry,
June 1, 2002;
159(6):
1018 - 1028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S B Hutton
Improved antisaccade performance in schizophrenia with risperidone
J. Neurol. Neurosurg. Psychiatry,
April 1, 2002;
72(4):
429 - 429.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
